Value Investor
Start free

Eikon Therapeutics

EIKN on Nasdaq. Biological products, (no diagnostic substances). Market value $408m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

Look carefully before going further

Why it could be worth it

What to watch out for

Read the warning sign in its own filings

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
n/a

We could not compute this from the filings.

Price to profit
n/a

The filings do not give us enough to work this out.

Return on capital
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: not known. Our list needs 70 on quality and 60 on price.

$7.51 a share, 7% above its 1-year low

Over the past year the price has ranged from $7.02 to $17.40.

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

Five-year fundamentals are not available yet.

Health checks

  • Free cash flow positiveNot enough data
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)Not enough data
  • Profit backed by cash (accruals)Not enough data
  • DebtUnknown
  • Revenue growth, five yearsUnknown

Dates

Next results (estimated)
n/a
Last annual report (10-K)
30 March 2026
Next quarterly (estimated, 10-Q)
12 November 2026

Who owns it

1 long-term investor we follow owns it, up from 0 last quarter. 77 funds in all.

Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

6 investors own more than 5%.

  • Tim Kutzkey
    Passive investor
    at least 11.6%
    (filed with 7 related holders)
    Since 6 February 2026
    What they said

    The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other…

    Read the filing
  • FMR LLC
    Passive investor
    at least 9.2%+2.1 pts
    (filed with 1 related holder)
    Since 30 June 2026
  • James B. Tananbaum
    Passive investor
    at least 7.7%
    (filed with 8 related holders)
    Since 4 February 2026
  • BlackRock Portfolio Management LLC
    Passive investor
    5.5%
    Since 31 March 2026
  • PERLMUTTER ROGER M
    Passive investor
    5.2%
    Since 4 February 2026
  • Innovation Endeavors III LP
    Passive investor
    at least 5.0%
    (filed with 5 related holders)
    Since 31 March 2026
  • Abu Dhabi Investment Authority
    Passive investor
    Sold down below 5%
    Since 30 September 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 2 insiders bought $12m of shares on the open market.

  • FRAZIER KENNETH C
    Director
    Bought
    Date
    4 February 2026
    Shares
    111,111
    Price
    $18.00
    Value
    $2m
  • Wolfe Josh
    Director
    Bought
    Date
    4 February 2026
    Shares
    277,776
    Price
    $18.00
    Value
    $5m
  • Wolfe Josh
    Director
    Bought
    Date
    4 February 2026
    Shares
    277,776
    Price
    $18.00
    Value
    $5m

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Eikon Therapeutics’ filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 30 Mar 2026, plus the 10-Q filed 13 Aug 2026 and 6 later 8-Ks.

  • Weak checks on its own accounts

    Serious

    The company said its checks on its own accounts did not work at year end. Mistakes could slip into the numbers.

    “Based on their evaluation as of the end of the period covered by this Annual Report, our Chief Executive Officer and Chief Financial Officer have concluded that, as of December 31, 2025, our disclosure controls and procedures were not effective because of the material weakness described below.”

    From the 10-K filed 30 March 2026, Item 9A. Controls and Procedures. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.